BOSTON, Nov. 12 /PRNewswire/ -- WHO and CDC have stated that the predictive accuracy of their annual formulations for human influenza vaccines is "suboptimal" -- often correct less than 50% of the time, especially for seniors. Perhaps in part because we are not yet accurate in our predictions of upcoming influenza strains, approximately 36,000 people die each year of flu in the United States alone.
As in the case of hurricanes, early warning of the location and intensity of virus outbreaks would allow us more rapidly and effectively to defend ourselves with strain-specific vaccines. This is now possible.
To provide this vital knowledge, Drs. Samuel and Elenore Bogoch of the Foundation for Research on the Nervous System and Replikins Ltd. of Boston ("Replikins") are presenting new technology at the 7th International Bird Flu Summit in Las Vegas November 13-14, 2008 that can accurately predict which viral strains are poised to attack human populations, and reveal the location from which this viral strain is going to strike. This service is being offered to WHO and CDC.
The key to this predictive technology is a new class of structural virus peptides that have been shown to be involved in the chemistry of rapid replication. The Drs. Bogoch called them "Replikins," and they are strictly defined by the concentration of lysine and histidine residues and the spacing between them. To demonstrate the correlation between the concentration of replikins and the lethality of influenza virus outbreaks, Replikins Ltd. has developed software called FluForecast(R), which counts the number of replikins in the sequences of each strain of flu virus across the years -- and thanks to the data in public databases like PubMed, we now can track as far as 90 years back.
What Replikins have found is that there's a strong correlation between the concentration of replikins and the lethality of an influenza virus outbreak. This allows us to determine in advance, using newly designed software, which viruses have the highest replikin concentrations -- and are thus poised to become the most lethal outbreak.
Replikin peptides are not distributed equally throughout the virus genome, but are concentrated in a specific area of the genome designated the Replikin Peak Gene (RPGene). When the replikin counts for certain viral strains are elevated, we see pandemics -- in which one to 50 million people die. Note that the replikins, like the pandemics, are strain-specific.
From its observations Replikins were able to predict an impending increase in human H5N1 mortality rate. In each host group -- goose, duck, chicken and human -- levels stayed low through 2004. But then Replikins saw a sudden spike in replikins particularly in chicken and human populations in 2005-06, which corresponded with increased epidemics in Asian countries. Which countries? Here again, Replikins looked at H5N1 replikin counts per country. Low levels - - below 4 -- were observed in each country until 2005-06, when it spiked most dramatically in Indonesia. Replikins thus predicted that Indonesia would be the first country to experience an H5N1 outbreak with higher human mortality, and this was proven to be correct in 2006-07.
So Replikins have demonstrated that tracking replikin counts not only works historically, but it can predict impending human mortality. Sequence the virus and you can tell whether it's relatively benign or likely to cause a pandemic -- the first time this has been possible.
Replikins is offering its FluForecast(R) service to WHO and CDC as a powerful new tool for tracking the appearance and lethality of new flu strains. By performing prompt replikin analysis of all human influenza sequences as they emerge, we can have advance warning of the intensity and location of future human influenza outbreaks. This will increase the accuracy of annual formulations for influenza vaccines, and will thereby hopefully reduce annual human influenza mortality rates. It is hoped that tracking replikins will save lives.
Beyond prediction, this new replikin-based technology also can be applied to combat influenza -- and to develop new vaccines that are more accurate and effective than current technology provides. Replikins have successfully demonstrated this capability when used against a virus in shrimp, which are susceptible to several devastating viral diseases. The replikin-based vaccine developed by Replikins to combat Taura Syndrome virus had a stunning result on the test population, protecting 91% of the shrimp against this deadly virus. Replikin vaccines work orally -- and can be synthesized far more quickly than conventional viral vaccines. The vaccine used to save the shrimp was manufactured in seven days. You can imagine what this type of rapid lead time would allow for making on-demand strain-specific influenza vaccines, which with traditional methods must be prepared nine months up to a year in advance.
Replikins is working to expand the capabilities of this vaccine technology and looks forward to making significant inroads to control H5N1 and other influenza populations.
Replikins are the viral tool of the future -- making accurate predictions in humans and animals now, through the FluForecast(R) service, and hopefully becoming a front-line weapon to stop viral pandemics in the future.
Contact: John McKenney, Replikins Ltd., 617-536-0220. An expanded version of this press release, with charts and additional data, will be posted on Replikins' website -- http://www.Replikins.com -- on November 13th.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
|SOURCE Replikins Ltd.|
Copyright©2008 PR Newswire.
All rights reserved